Regeneron
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New York, United States · 10K+ Employees
View Company Info for Free
Overview
Headquarters
777 Old Saw Mill River Rd, Tarrytown, Ne...Phone Number
(914) 847-7000Website
www.regeneron.comRevenue
$14.9 BillionStock Symbol
REGNIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
20
1
3
3
3
2
About Regeneron
Regeneron is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. The company focuses on using advanced science and proprietary technologies to create life-changing treatments for conditions such as cancer, eye diseases, inflammatory disorders, and rare diseases.Explore more
Regeneron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regeneron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Regeneron launches new products
Click to see if Regeneron had a recent Job posting/layoffs
Regeneron, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Regeneron has recently received funding, and reach out quickly before it becomes old news!
Check out if Regeneron is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Regeneron has new funding data
Congratulate Masked Content for being promoted to Masked Content at Regeneron
Earning: See what the market has to say on Regeneron recently announced quarterly report
Recommended Actions
Find VP level buyers at Regeneron
Find 2 more new buyers
Compare Similar Companies to Regeneron
Compare insights from companies similar to Regeneron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$37.2B
10K+
Public
$2B
1980
CC
Carlos ColladoChief Financial Officer, Country & LATAM Distributors (Mexico)
$29.7B
10K+
Public
$296.3M
1987
CD
Courtney DesmondChief of Staff To Senior Vice President Chief Ethics and Compliance Officer
Company Profile Activity
Activity Insights
Regeneron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Regeneron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Regeneron.
Regeneron financials insights
Gather financial insights about Regeneron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1991
Stock Offering
$91.4M
2010
Stock Offering
$174.7M
2011
Debt
$400M
Regeneron Tech Stack
A closer look at the technologies used by Regeneron
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Regeneron News & Media
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosingRegeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab is the most […]Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regeneron
Sign Up For FreeTo access detailed company insights
Regeneron is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. The company focuses on using advanced science and proprietary technologies to create life-changing treatments for conditions such as cancer, eye diseases, inflammatory disorders, and rare diseases.... Read More
